NCT07109765 Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
| NCT ID | NCT07109765 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College |
| Condition | Hidradenitis Suppurativa (HS) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-06-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
Eligibility Criteria
Inclusion Criteria: * age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors Exclusion Criteria: * active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results
Frequently Asked Questions
Who can join the NCT07109765 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hidradenitis Suppurativa (HS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07109765 currently recruiting?
Yes, NCT07109765 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking Union Medical College to inquire about joining.
Where is the NCT07109765 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07109765 clinical trial?
NCT07109765 is sponsored by Peking Union Medical College. The trial plans to enroll 50 participants.